Hyrimoz 40 mg solution for injection in pre-filled syringe
Sponsors
Diakonhjemmet Sykehus AS, University Of Medicine And Pharmacy Carol Davila Bucharest, Medical University Of Vienna, Karolinska University Hospital, Universiteit Maastricht, Sint Maartenskliniek Stichting, Oslo Universitetssykehus HF
Conditions
Crohn's diseaseJuvenil Idiopatic ArthritisRheumatoid arthritis
Phase 4
A multi-center, open, randomized, 18-month, parallel-group, superiority study to compare the effect of proactive therapeutic drug monitoring versus standard of care with regards to maintenance of sustained disease control without flare in adults with rheumatoid arthritis treated with a subcutaneous tumor necrosis factor inhibitor
RecruitingCTIS2023-510184-35-00
Start: 2024-08-20Target: 410Updated: 2025-09-12
Control Crohn Safe with episodic adalimumab monotherapy as first line treatment study
RecruitingCTIS2024-516002-33-01
Start: 2019-12-23Target: 158Updated: 2024-12-17
DISCO-RA:DIScontinuation of COncomitant disease modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis patients also using TNF inhibitors - a randomized long-term non-inferiority strategy trial
Not yet recruitingCTIS2026-525316-33-00
Target: 202Updated: 2026-06-09
Treatment strategies for juvenile idiopathic arthritis patients with sustained inactive disease: A phase 4, multicentre, randomised trial comparing maintenance versus tapered TNF alpha inhibitor monotherapy - the Treat-JIA trial
Not yet recruitingCTIS2026-525611-13-00
Target: 90Updated: 2026-06-23